Strategies for cancer immunotherapy using induced pluripotency stem cells-based vaccines

Detalhes bibliográficos
Autor(a) principal: Bernardes de Jesus, Bruno
Data de Publicação: 2020
Outros Autores: Neves, Bruno Miguel, Ferreira, Manuela, Nóbrega-Pereira, Sandrina
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/47492
Resumo: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
id RCAP_9ff79ccd9e73b65692951b36bf9b5907
oai_identifier_str oai:repositorio.ul.pt:10451/47492
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Strategies for cancer immunotherapy using induced pluripotency stem cells-based vaccinesiPSCsCancerReprogrammingImmunotherapyNeoantigensVaccines© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).Despite improvements in cancer therapy, metastatic solid tumors remain largely incurable. Immunotherapy has emerged as a pioneering and promising approach for cancer therapy and management, and in particular intended for advanced tumors unresponsive to current therapeutics. In cancer immunotherapy, components of the immune system are exploited to eliminate cancer cells and treat patients. The recent clinical successes of immune checkpoint blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer treatment. Despite their potential success, current approaches depend on efficient tumor antigen presentation which are often inaccessible, and most tumors turn refractory to current immunotherapy. Patient-derived induced pluripotent stem cells (iPSCs) have been shown to share several characteristics with cancer (stem) cells (CSCs), eliciting a specific anti-tumoral response when injected in rodent cancer models. Indeed, artificial cellular reprogramming has been widely compared to the biogenesis of CSCs. Here, we will discuss the state-of-the-art on the potential implication of cellular reprogramming and iPSCs for the design of patient-specific immunotherapeutic strategies, debating the similarities between iPSCs and cancer cells and introducing potential strategies that could enhance the efficiency and therapeutic potential of iPSCs-based cancer vaccines.This research was funded by Fundação para a Ciência e Tecnologia (FCT), and FEDER, LISBOA-01-0145-FEDER-028534, project co-funded by FEDER, through POR Lisboa 2020—Programa Operacional Regional de Lisboa, PORTUGAL 2020, FEDER—Fundo Europeu de Desenvolvimento Regional through the COMPETE 2020—Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, by Portuguese funds through FCT, in the framework of the project UIDB/04501/2020 to iBiMED and by the European Commission (ERA-CVD Joint Call 2018, grant#INNOVATION) through FCT and the Portuguese Ministry of Health, through the Directorate General of Health (DGS).MDPIRepositório da Universidade de LisboaBernardes de Jesus, BrunoNeves, Bruno MiguelFerreira, ManuelaNóbrega-Pereira, Sandrina2021-04-20T16:21:16Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/47492engCancers (Basel). 2020 Nov 30;12(12):358110.3390/cancers121235812072-6694info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:50:27Zoai:repositorio.ul.pt:10451/47492Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:59:31.345242Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Strategies for cancer immunotherapy using induced pluripotency stem cells-based vaccines
title Strategies for cancer immunotherapy using induced pluripotency stem cells-based vaccines
spellingShingle Strategies for cancer immunotherapy using induced pluripotency stem cells-based vaccines
Bernardes de Jesus, Bruno
iPSCs
Cancer
Reprogramming
Immunotherapy
Neoantigens
Vaccines
title_short Strategies for cancer immunotherapy using induced pluripotency stem cells-based vaccines
title_full Strategies for cancer immunotherapy using induced pluripotency stem cells-based vaccines
title_fullStr Strategies for cancer immunotherapy using induced pluripotency stem cells-based vaccines
title_full_unstemmed Strategies for cancer immunotherapy using induced pluripotency stem cells-based vaccines
title_sort Strategies for cancer immunotherapy using induced pluripotency stem cells-based vaccines
author Bernardes de Jesus, Bruno
author_facet Bernardes de Jesus, Bruno
Neves, Bruno Miguel
Ferreira, Manuela
Nóbrega-Pereira, Sandrina
author_role author
author2 Neves, Bruno Miguel
Ferreira, Manuela
Nóbrega-Pereira, Sandrina
author2_role author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Bernardes de Jesus, Bruno
Neves, Bruno Miguel
Ferreira, Manuela
Nóbrega-Pereira, Sandrina
dc.subject.por.fl_str_mv iPSCs
Cancer
Reprogramming
Immunotherapy
Neoantigens
Vaccines
topic iPSCs
Cancer
Reprogramming
Immunotherapy
Neoantigens
Vaccines
description © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-01-01T00:00:00Z
2021-04-20T16:21:16Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/47492
url http://hdl.handle.net/10451/47492
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Cancers (Basel). 2020 Nov 30;12(12):3581
10.3390/cancers12123581
2072-6694
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134541070204928

Registros relacionados